Human ErbB3/Her3 Antibody

Catalog # Availability Size / Price Qty
MAB3481-SP
MAB3481-500
MAB3481-100
Cell Proliferation Induced by NRG1‑ beta 1/HRG1‑ beta 1 and Neutralization by Human ErbB3/Her3 Antibody.
1 Image
Product Details
Citations (21)
FAQs
Supplemental Products
Reviews (3)

Human ErbB3/Her3 Antibody Summary

Species Reactivity
Human
Specificity
Detects human ErbB3/Her3 in ELISAs. Does not cross-react with recombinant EGF R.
Source
Monoclonal Mouse IgG1 Clone # 66223
Purification
Protein A or G purified from hybridoma culture supernatant
Immunogen
Mouse myeloma cell line NS0-derived recombinant human ErbB3/Her3
Ser20-Thr643
Accession # P21860
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.
Label
Unconjugated

Applications

Recommended Concentration
Sample
Flow Cytometry
2.5 µg/106 cells
MCF‑7 human breast cancer cell line
CyTOF-ready
Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.
 

Human ErbB3/Her3 Sandwich Immunoassay

Recommended Concentration
Reagent
ELISA Capture (Matched Antibody Pair)
2-8 µg/mL 

Use in combination with:

Detection Reagent: Human ErbB3/Her3 Biotinylated Antibody (Catalog # BAM348)

Standard: Recombinant Human ErbB3/Her3 Fc Chimera Protein, CF (Catalog # 348-RB)

Neutralization
Measured by its ability to neutralize NRG1‑ beta 1/HRG1‑ beta 1-induced proliferation in the MCF‑7 human breast cancer cell line. The Neutralization Dose (ND50) is typically 0.0075-0.03 µg/mL in the presence of 10 ng/mL Recombinant Human NRG1‑ beta 1/HRG1‑ beta 1 Extracellular Domain.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Neutralization Cell Proliferation Induced by NRG1‑ beta 1/HRG1‑ beta 1 and Neutralization by Human ErbB3/Her3 Antibody. View Larger

Cell Proliferation Induced by NRG1‑ beta 1/HRG1‑ beta 1 and Neutralization by Human ErbB3/Her3 Antibody. Recombinant Human NRG1-1 beta 1/HRG1-1 beta 1 (Catalog # 377-HB) stimulates proliferation in the MCF-17 human breast cancer cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Human NRG1-1 beta 1/HRG1-1 beta 1 (10 ng/mL) is neutralized (green line) by increasing concentrations of Human ErbB3/Her3 Monoclonal Antibody (Catalog # MAB3481). The ND50 is typically 0.0075-0.03 µg/mL.

Preparation and Storage

Reconstitution
Reconstitute at 0.5 mg/mL in sterile PBS.
Loading...
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: ErbB3/Her3

ErbB3, also called Her3 (human epidermal growth factor receptor 3), is a type I membrane glycoprotein that is a member of the ErbB family of tyrosine kinase receptors. ErbB family members serve as receptors for the epidermal growth factor (EGF) family of growth factors. Among ErbB family members, ErbB3 is unique in that it contains a defective kinase domain. ErbB3 is expressed in keratinocytes, melanocytes, skeletal muscle cells, embryonic myoblasts and Schwann cells. Monomeric ErbB3 serves as a low affinity receptor for the heregulins (HRG). ErbB3 heterodimerizes with ErbB2 to form a high affinity receptor complex. In contrast, ErbB3 homodimerization or heterodimerization with ErbB4 forms a low affinity heregulin-binding complex. Because ErbB3 contains a defective kinase domain, the kinase domain of ErbB2 is responsible for initiating the tyrosine phosphorylation signal through the heterodimeric receptor. It has been found that a discrete three amino acid signal in the ErbB3 cytoplasmic domain is critical for transactivation of ErbB2. The cytoplasmic domain of ErbB3 also contains six consensus binding motifs for the SH2 domain of the regulatory p85 subunit of phosphoinositide 3-kinase (PI 3-kinase, PI3K) as well as one proline-rich consensus binding motif for the SH3 domain of p85. Human ErbB3 consists of 1342 amino acids (aa) with a 19 aa signal sequence, a 624 aa extracellular domain, a 21 aa transmembrane region, and a 678 aa cytoplasmic domain. ErbB3 appears to play roles in development, cancer, communication at the neuromuscular junction, and regulation of cell growth and differentiation.

References
  1. Kraus, M.H. et. al. (1989) Proc. Natl. Acad. Sci. USA 86:9193.
  2. Plowman, G.D. et. al. (1990) Proc. Natl. Acad. Sci. USA 87:4905.
  3. Carraway, K.L. 3rd et. al. (1994) J. Biol. Chem. 269:14303.
  4. Emkey, R. and C.R. Kahn (1997) J. Biol. Chem. 272:31172.
  5. Sundaresan, S. et. al. (1998) Endocrinology 139:4756.
  6. Hellyer, N.J. et. al. (1998) Biochem. J. 333:757.
  7. Schaefer, G. et. al. (1999) J. Biol. Chem. 274:859.
  8. Hellyer, N.J. et. al. (2001) J. Biol. Chem. 276:42153.
  9. Schlessinger, J. (2000) Cell 103:211.
  10. Daly, R.J. (1999) Growth Factors 16:255.
Long Name
Receptor Tyrosine Protein Kinase ErbB3
Entrez Gene IDs
2065 (Human); 13867 (Mouse)
Alternate Names
c-erbB3; EC 2.7.10; EC 2.7.10.1; ErbB3; ErbB-3; erbB3-S; HER3; HER3c-erbB-3; LCCS2; lethal congenital contracture syndrome 2; MDA-BF-1; MGC88033; p180-ErbB3; p45-sErbB3; p85-sErbB3; Proto-oncogene-like protein c-ErbB-3; receptor tyrosine-protein kinase erbB-3; Tyrosine kinase-type cell surface receptor HER3; v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian)

Product Datasheets

You must select a language.

x

Citations for Human ErbB3/Her3 Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

21 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Adding of neurotensin to non-small cell lung cancer cells increases tyrosine phosphorylation of HER3
    Authors: TW Moody, I Ramos-Alva, RT Jensen
    Peptides, 2022-08-03;156(0):170858.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  2. SERS characterization of colorectal cancer cell surface markers upon anti‐EGFR treatment
    Authors: Nana Lyu, Bernadette Pedersen, Elena Shklovskaya, Helen Rizos, Mark P. Molloy, Yuling Wang
    Exploration (Beijing)
  3. The G Protein–Coupled Receptor PAC1 Regulates Transactivation of the Receptor Tyrosine Kinase HER3
    Authors: Terry W. Moody, Lingaku Lee, Robert T. Jensen
    Journal of Molecular Neuroscience
  4. Effect of Cetuximab-Conjugated Gold Nanoparticles on the Cytotoxicity and Phenotypic Evolution of Colorectal Cancer Cells
    Authors: Ralph El Hallal, Nana Lyu, Yuling Wang
    Molecules
  5. Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of pancreatic cancer cell lines and the identification of antagonistic combinations: Implications for future clinical trials in pancreatic cancer
    Authors: T Khan, AM Seddon, AG Dalgleish, S Khelwatty, N Ioannou, S Mudan, H Modjtahedi
    Oncol Rep, 2020-10-22;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  6. Neuropeptide bombesin receptor activation stimulates growth of lung cancer cells through HER3 with a MAPK-dependent mechanism.
    Authors: Lingaku Lee, Irene Ramos-Alvarez, Terry W. Moody, Samuel A. Mantey, Robert T. Jensen
    Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
  7. Tracking extracellular vesicle phenotypic changes enables treatment monitoring in melanoma
    Authors: J Wang, A Wuethrich, AA Sina, RE Lane, LL Lin, Y Wang, J Cebon, A Behren, M Trau
    Sci Adv, 2020-02-26;6(9):eaax3223.
    Species: Human
    Sample Types: Cell Lysates, Whole Cells
    Applications: Flow Cytometry, Western Blot
  8. A high-resolution study of in situ surface-enhanced Raman scattering nanotag behavior in biological systems
    Authors: J Wang, W Anderson, J Li, LL Lin, Y Wang, M Trau
    J Colloid Interface Sci, 2018-11-12;537(0):536-546.
    Species: Human
    Sample Types: Recombinant Protein
    Applications: Dynamic Light Scattering
  9. Soluble HER3 predicts survival in bladder cancer patients
    Authors: AA Memon, SC Gilliver, M Borre, J Sundquist, K Sundquist, E Nexo, BS Sorensen
    Oncol Lett, 2017-11-22;15(2):1783-1788.
    Species: Human
    Sample Types: Plasma
    Applications: ELISA Development (Capture)
  10. 89Zr-mAb3481 PET for HER3 tumor status assessment during lapatinib treatment
    Authors: Martin Pool, Arjan Kol, Steven de Jong, Elisabeth G. E. de Vries, Marjolijn N. Lub-de Hooge, Anton G.T. Terwisscha van Scheltinga
    mAbs
  11. Neuregulin 1 allosterically enhances the anti-tumor effects of the non-competing anti-HER3 antibody 9F7-F11 by increasing its binding to HER3
    Authors: C Le Clorenn, H Bazin, O Dubreuil, C Larbouret, C Ogier, Y Lazrek, V Garambois, MA Poul, P Mondon, JM Barret, G Mathis, JF Prost, A Pèlegrin, T Chardès
    Mol. Cancer Ther., 2017-05-15;0(0):.
    Species: Human
    Sample Types: Recombinant Protein, Whole Cells
    Applications: ELISA Development, Neutralization
  12. Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs
    Authors: Helmout Modjtahedi
    Int. J. Oncol., 2016-09-05;49(5):1825-1838.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  13. Blood‐based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)
    Authors: Ace J. Hatch, Alexander B. Sibley, Mark D. Starr, J. Chris Brady, Chen Jiang, Jingquan Jia et al.
    Cancer Medicine
  14. Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibition
    Authors: NIKOLAOS IOANNOU, ALAN M. SEDDON, ANGUS DALGLEISH, DAVID MACKINTOSH, FLAVIO SOLCA, HELMOUT MODJTAHEDI
    International Journal of Oncology
  15. Neuregulin-1-mediated ErbB2-ErbB3 signalling protects human trophoblasts against apoptosis to preserve differentiation
    Authors: V Fock, K Plessl, P Draxler, GR Otti, C Fiala, M Knöfler, J Pollheimer
    J. Cell. Sci, 2015-10-21;128(23):4306-16.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  16. A novel antibody engineering strategy for making monovalent bispecific heterodimeric IgG antibodies by electrostatic steering mechanism.
    Authors: Liu Z, Leng E, Gunasekaran K, Pentony M, Shen M, Howard M, Stoops J, Manchulenko K, Razinkov V, Liu H, Fanslow W, Hu Z, Sun N, Hasegawa H, Clark R, Foltz I, Yan W
    J Biol Chem, 2015;290(12):7535-62.
    Species: Human
    Sample Types: Whole Cells
    Applications: ELISA Development (Capture)
  17. Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells
    Authors: N Ioannou, A G Dalgleish, A M Seddon, D Mackintosh, U Guertler, F Solca et al.
    British Journal of Cancer
  18. Growth response of human colorectal tumour cell lines to treatment with afatinib (BIBW2992), an irreversible erbB family blocker, and its association with expression of HER family members.
    Authors: Khelwatty SA, Essapen S, Seddon AM, Modjtahedi H
    Int. J. Oncol., 2011-05-25;39(2):483-91.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  19. Microbead arrays for the analysis of ErbB receptor tyrosine kinase activation and dimerization in breast cancer cells.
    Authors: Khan IH, Zhao J, Ghosh P, Ziman M, Sweeney C, Kung HJ, Luciw PA
    Assay Drug Dev Technol, 2010-02-01;8(1):27-36.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Immunoprecipitation, Luminex Development
  20. Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer.
    Authors: Lin SH, Lee YC, Choueiri MB, Wen S, Mathew P, Ye X, Do KA, Navone NM, Kim J, Tu SM, Yu-Lee LY, Logothetis CJ
    Clin. Cancer Res., 2008-06-15;14(12):3729-36.
    Species: Human
    Sample Types: Cell Culture Supernates
    Applications: ELISA Development
  21. A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation.
    Authors: Lin SH, Cheng CJ, Lee YC, Ye X, Tsai WW, Kim J, Pasqualini R, Arap W, Navone NM, Tu SM, Hu M, Yu-Lee LY, Logothetis CJ
    Oncogene, 2008-05-19;27(39):5195-203.
    Species: Human
    Sample Types: Plasma
    Applications: ELISA Development

FAQs

No product specific FAQs exist for this product, however you may

View all Antibody FAQs
Loading...

Reviews for Human ErbB3/Her3 Antibody

Average Rating: 5 (Based on 3 Reviews)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used Human ErbB3/Her3 Antibody?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Human ErbB3/Her3 Antibody
By Anonymous on 10/13/2021
Application: Flow Sample Tested: SK-Mel-28 human malignant melanoma cell line Species: Human

Human ErbB3/Her3 Antibody
By Jenna Nguyen on 05/07/2019
Application: B/N Sample Tested: ?TC-6 mouse beta cell insulinoma cell line Species: Mouse

Human ErbB3/Her3 Antibody
By Jenna Nguyen on 04/05/2019
Application: Affinity Purification Sample Tested: 3T3-L1 mouse embryonic fibroblast adipose-like cell line Species: Mouse